Allogeneic ATA 188

Drug Profile

Allogeneic ATA 188

Alternative Names: Allogeneic EBV-directed T-cell therapy; ATA188; EBV-CTLs; EBV-targeted T-cell; Epstein-Barr Virus-directed cytotoxic T lymphocytes; Off-the-shelf ATA188

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics
  • Class Gene therapies; Immunotherapies; Neuroprotectants; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis
  • Preclinical Solid tumours

Most Recent Events

  • 22 Mar 2018 Phase-I clinical trials in Multiple sclerosis (Treatment-experienced) in USA (IV) (NCT03283826)
  • 10 Jan 2018 US FDA approves IND application for ATA 188 in Multiple sclerosis
  • 27 Oct 2017 Preclinical trials in Solid tumours in USA (unspecified route) (Atara Biotherapeutics pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top